-
Does China still need new crown oral drugs?
Time of Update: 2023-02-03
The peak of severe disease is approaching, and it is difficult to find a new crown oral medicine. On the 26th, after verification and confirmation by a number of media, Beijing will soon distribute Pa
-
Where is the innovation and transformation path for local pharmaceutical companies?
Time of Update: 2023-02-03
From the sales of generic drugs in the past to the record high number of clinical applications for new drugs in recent years, "innovation transformation" has become an important proposition for the sustainable development of local pharmaceutical companies.
-
"Three Doctors Collaborative Perspective" explores the way to solve the difficult problem of innovative drug admission
Time of Update: 2023-02-03
On December 23, the National Health Insurance Administration issued the Notice on Comprehensive Investigation and Removal of Unreasonable Restrictions on Medical Insurance[1], requiring all provinces
-
In 2022, more than 270 Chinese innovative drug companies will complete financing, and more than 40% will be established in the past three years!
Time of Update: 2023-02-03
Resources: Resources: [1] Official information of each company and official press releases of relevant investors [1] Official information of each company and official press releases of relevant investors Combing through the research fields of these companies, we found that new molecular therapies such as cell therapy, gene therapy, RNA therapy, targeted protein degradation drugs, and new antibodies have become one of the main research directions of emerging enterprises.
-
Academician Gao Fu bravely shoulders national responsibilities and actively promotes the development of China's bioeconomy and bioindustry
Time of Update: 2023-02-03
Overview of the paperOverview of the paper The people of the country bravely shoulder the national responsibility and actively promote the development of China's bioeconomy and bioindustryThe people
-
After the "Class B tube", the new generation of oral special drug ensetivir may become a "new weapon" for China's anti-epidemic. According to sources, Shiono is willing to localize the industrial chain in China to ensure stable supply
Time of Update: 2023-02-03
We thank all the medicine people for their efforts!First of all, from the applicable population, P drug is conditionally approved for mild to moderate new crown infection with high risk factors for severe disease, while the indications approved by ensetvir in Japan do not have similar restrictions and can be used at the early stage of the patient's confirmed infection.
-
Look here! These experts were selected into the list of clinical external candidates for CDE's pediatric drug technical review
Time of Update: 2023-02-03
docx In order to ensure the scientific fairness of children's drug review, study and solve key and difficult problems in children's drug research and development, and expand professional fields and expert strength, in accordance with the "Measures for the Management of External Experts of the Drug Evaluation Center" and with the consent of the State Medical Products Administration, our center organized and carried out the selection of clinical external experts for children's drug technical review.
-
CAR-NK pioneer: Fate shares plunged 48%, terminating its partnership with Johnson & Johnson
Time of Update: 2023-02-03
summarysummaryAlthough the clinical popularity of CAR-NK has not decreased, it is still expected to have a major breakthrough in efficacy.
Although the clinical popularity of CAR-NK has not decreased, it is still expected to have a major breakthrough in efficacy.
-
From the perspective of CDE guidelines, what are regulators focusing on in 2022?
Time of Update: 2023-02-03
Compared with the ups and downs of the general environment, the drug regulatory policies in 2022 are generally stable. From the perspective of guiding principles, regulators pay more and more attentio
-
$3.335 billion: Merck and Eli Lilly bet on PDC therapy
Time of Update: 2023-02-03
235 billion Under this protocol, PeptiDream will utilize its proprietary Peptide Discovery Platform System ("PDPS") technology to identify high-affinity macrocyclic peptide ligands selected by Lilly for selected targets of interest, capable of delivering Lilly-conjugated payloads to certain cells and tissues of interest to Lilly.
-
Deeply remembering Academician Jiang Hualiang
Time of Update: 2023-02-03
His untimely death is a great loss for the Chinese pharmaceutical community and innovative pharmaceutical industry, and we are all deeply shocked and saddened!——Yang Dajun, Chairman and CEO of Ascentage PharmaceuticalAcademician Jiang Hualiang, an important leader of the association, unfortunately passed away.
-
Paxlovid is still difficult to grab, why have more domestic new crown oral drugs not been approved?
Time of Update: 2023-02-03
As early as March and April 2022, shortly after the State Food and Drug Administration approved Paxlovid, three Chinese pharmaceutical companies have entered phase III clinical trials of anti-new coronavirus oral drugs, namely: VV116 from Junshi Biologics, Proclomide from Pioneer Pharmaceuticals and azvudine from Real Biologics.
-
China's pharmaceutical industry in 2022: these keywords & hot events
Time of Update: 2023-02-03
"Heavy blow"Fortunately, the journey of twists and turns is accompanied by a ray of hope: in November 2022, Henlius' Hans-like (serplulimab) bridging study in the United States completed the first drug administration; In December, EMA accepted Junshi Tuoyi's marketing authorization application; East China Pharmaceutical, Tonghua Dongbao Liraglutide injection have comprehensively expanded into emerging countries such as the Middle East and North Africa.
-
Heavy! 2022 Pharmaceutical Industry 6 Figure Review
Time of Update: 2023-02-03
2022 is not easy, hospital visits and business operations are still deeply affected by the epidemic, and routine medical insurance negotiations have been postponed due to the epidemic, but the achieve
-
China's CAR-T cell therapy: rapid rise, bright future
Time of Update: 2023-02-03
IF=30. 153) published a review that reviews and summarizes the ten-year history of the development and clinical application of CAR-T cell therapy. In terms of innovation and clinical application, Chi
-
Another biological drug "upstart" went to Hong Kong to ring the bell! What are the highlights of Boan Biotech, which holds two commercial products?
Time of Update: 2023-02-03
Since the second half of this year, the Hong Kong IPO market has gradually shown signs of recovery. On December 30, Shandong Boan Biotechnology Co. , Ltd. (hereinafter referred to as "Boan Biotechnolo
-
Crazy new crown "special drugs": scalpers, pins and imitations
Time of Update: 2023-02-03
Another international mainstream anti-new coronavirus small molecule drug, Merck's Molnupiravir (Monupivir), the original drug has not yet been approved, and people have purchased generic drugs from LaosBehind Paxlovid's popularity is the increase in the number of severe patients with new crown disease in China, and the huge demand for new crown infected people with high-risk factors to reduce the probability of severe disease.
-
Jiang Ningjun joins Hengrui Pharmaceutical! Together with Sun Piaoyang and Zhang Lianshan, he formed a strategic R&D trio
Time of Update: 2023-02-03
From retirement to leaving the mountain, as of January 3, 2023, Sun Piaoyang has been in charge of Hengrui for more than 540 days. At present, Hengrui Pharmaceutical is still not performing well in th
-
Domestic oncology NGS enterprises go overseas to find technological and commercial leaps
Time of Update: 2023-02-03
On January 3, Burnstone Medical announced that its pan-cancer early screening products were recognized by the FDA as breakthrough therapies.
On January 3, Burnstone Medical announced that its pan-cancer early screening products were recognized by the FDA as breakthrough therapies.
-
Widest coverage! The marketing application of Pfizer pentavalent meningococcal vaccine was accepted by the FDA
Time of Update: 2023-02-03
Together, the five serogroups (A, B, C, W, Y) account for 96% of all invasive meningococcal disease cases globally Information Reference: Information Reference: Annaliesa, senior vice president and chief scientific officer of Pfizer vaccine research and development "The FDA's acceptance of our pentavalent meningococcal vaccine candidate is an important step in helping individuals and communities prevent the most common types of meningococcal disease," Anderson said.
